<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[WIN Consortium 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=21463></link><description><![CDATA[WIN Consortium 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 03:43:25 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2015/04/12_3554153577_20150413102935_1795744694.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[WIN 2019 심포지엄: 위노베이션과 정밀종양학의 글로벌 확산]]></title><link>https://www.newswire.co.kr/newsRead.php?no=888466</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--제11차 WIN 정밀종양학 심포지엄(WIN Symposium in Precision Oncology)이 2019년 6월 23일부터 24일까지 양일간 프랑스 파리에서 열린다.  지난 11년 동안 미국임상종양학회(ASCO®)의 지지를 받아온 WIN 심포지엄에는 열정적인 연사들이 대거 참여해 정밀종양학의 혁신과 글로벌 확산에 관해 논의하게 된다. 또한 이번 행사의 의장을 맡은 리처드 실스키(Richard L. Schils...]]></description><pubDate>Mon, 20 May 2019 10:07:32 +0900</pubDate></item><item><title><![CDATA[WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology]]></title><link>https://www.newswire.co.kr/newsRead.php?no=888460</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019.  ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology acr...]]></description><pubDate>Mon, 20 May 2019 09:42:38 +0900</pubDate></item><item><title><![CDATA[Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=886920</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for t...]]></description><pubDate>Tue, 23 Apr 2019 00:00:00 +0900</pubDate></item><item><title><![CDATA[새로운 통합적 종양 프로파일링 기법이 말기 암 환자들에게 새로운 치료 옵션을 제공]]></title><link>https://www.newswire.co.kr/newsRead.php?no=886929</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN 컨소시엄** 주도하의 첫 의학연구인 WINTHER의 산물로서 ‘게놈 및 유전자 전사 기술이 정밀 암 의학의 발전을 이끌다 : WINTHER 실험’이라는 제목의 논문이 22일 내추어 메디신*(Nature Medicine) 저널에 게재되었다.  여기서는 다른 어떠한 단일 종양 돌연변이 DNA 표준 테스트 방법에 비해서도 DNA 테스트와 같이 실시한 RNA 프로파일링을 통해서 보다 많은 수의 말기...]]></description><pubDate>Tue, 23 Apr 2019 00:00:00 +0900</pubDate></item><item><title><![CDATA[FDA Allows WIN Consortium to Proceed with Targeted Tri-Therapy Clinical Trial in First Line Treatment of Metastatic Non Small Cell Lung Cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=854352</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--WIN Consortium (WIN) received the US Food and Drug Administration (FDA)’s approval to start the clinical investigation of a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced Non Small Cell Lung Cancer (NSCLC). The Survival Prolongation by Rationale Innovative Genomic...]]></description><pubDate>Wed, 09 Aug 2017 19:00:00 +0900</pubDate></item><item><title><![CDATA[FDA, WIN 컨소시엄에 전이성 비소세포폐암 1차항암요법을 위한 3중 표적치료제 임상시험 승인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=854353</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN 컨소시엄(WIN Consortium, 이하WIN)이 미국식약청(US Food and Drug Administration, 이하 FDA)으로부터 진행성 비소세포폐암(Non Small Cell Lung Cancer, NSCLC) 환자들의 1차 항암치료를 위해 3개의 표적 치료제를 혼합해 사용하는 새로운 요법의 임상시험 개시를 승인받았다.  ‘Survival Prolongation by Rationale Innovative Genomics(SPRING, 근원적인 혁신 유전...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2017/08/3698601005_20170809170457_2925649704.jpg]]></url></image><pubDate>Wed, 09 Aug 2017 19:00:00 +0900</pubDate></item><item><title><![CDATA[머크, 맞춤형 암 치료제 개발을 위한 세계 혁신 네트워크(WIN) 컨소시엄(파리)에 합류]]></title><link>https://www.newswire.co.kr/newsRead.php?no=851647</link><description><![CDATA[PARIS & DARMSTADT, Germany--(Business Wire/뉴스와이어)--맞춤형 암 치료제 개발을 위한 세계 혁신 네트워크(WIN) 컨소시엄이 미국과 캐나다에서 EMD세로노(EMD Serono)라는 이름으로 사업을 추진하고 있는 머크(Merck)가 WIN 컨소시엄 회원으로 합류했다고 15일 발표했다.  WIN은 암 환자들의 생존에 유의미한 영향을 주기 위해 신세대 생체지표가 주도하는 치료제의 임상시험과 전세계적으로 실시하는 생체지표 발견 프로그램에 ...]]></description><pubDate>Fri, 16 Jun 2017 13:55:00 +0900</pubDate></item><item><title><![CDATA[Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium (Paris)]]></title><link>https://www.newswire.co.kr/newsRead.php?no=851650</link><description><![CDATA[PARIS & DARMSTADT, Germany--(Business Wire/Korea Newswire)--Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, becomes a member of the WIN Consortium. WIN is a network of 40 academic institutions and industries across the globe, focusing on new generation biom...]]></description><pubDate>Fri, 16 Jun 2017 13:55:00 +0900</pubDate></item><item><title><![CDATA[WIN 2017 Symposium, Expediting Global Innovation in Precision Cancer Medicine]]></title><link>https://www.newswire.co.kr/newsRead.php?no=845049</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--WIN 2017 Symposium will be held in Paris, France from June 26-27, 2017. The CME accredited WIN2017 is an exceptional scientific event dedicated to “Expediting Global Innovation in Precision Cancer Medicine’’ addressed to all cancer care professionals.  “The 2016 WIN symposium brought together some of most distinguished lecturers from around the ...]]></description><pubDate>Tue, 14 Feb 2017 11:30:00 +0900</pubDate></item><item><title><![CDATA[WIN 2017 심포지엄, 정밀 암 치료의 세계적 혁신 촉진]]></title><link>https://www.newswire.co.kr/newsRead.php?no=845050</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN 2017 심포지엄(WIN 2017 Symposium)이 2017년 6월 26~27일에 프랑스 파리에서 개최될 예정이다. CME 인증을 받은 WIN 2017은 모든 암 치료 전문가들이 ‘정밀 암 치료의 세계적 혁신 촉진(Expediting Global Innovation in Precision Cancer Medicine)’을 위해 한자리에 모이는 특별 과학 행사다.   WIN 2016 심포지엄에서 기조 강연을 했던 ASCO® 2017-2018 회장 브루스...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2017/02/3698601005_20170214113335_2771584670.jpg]]></url></image><pubDate>Tue, 14 Feb 2017 11:30:00 +0900</pubDate></item><item><title><![CDATA[Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine is Very Proud to Announce That Institut Curie, France Has Joined Its Consortium]]></title><link>https://www.newswire.co.kr/newsRead.php?no=827654</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--“We are very proud to welcome Institut Curie to WIN,” said Dr. John Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for Personalized Cancer Therapy and past President of MD Anderson Cancer Center. “The Institut Curie is undeniably a leading European cancer research center with remarkable research that will constitute a major as...]]></description><pubDate>Wed, 01 Jun 2016 19:00:00 +0900</pubDate></item><item><title><![CDATA[맞춤형 암 치료제 개발을 위한 세계 혁신 네트워크 (WIN) 컨소시엄에 프랑스의 퀴리 연구소 합류]]></title><link>https://www.newswire.co.kr/newsRead.php?no=827655</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN의 회장 겸 칼리파 맞춤형 암치료 연구소(Khalifa Institute for Personalized Cancer Therapy) 이사이며 MD앤더슨 암센터(MD Anderson Cancer Center) 전 회장인 존 멘델손(John Mendelsohn) 박사는 “퀴리 연구소(Institut Curie)의 WIN 참여를 매우 자랑스럽게 생각한다”며 “퀴리 연구소는 주목할 만한 연구 실적을 가진 유럽의 선도적 암 연구소로서 WIN을 구성하는 ...]]></description><pubDate>Wed, 01 Jun 2016 19:00:00 +0900</pubDate></item><item><title><![CDATA[The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes]]></title><link>https://www.newswire.co.kr/newsRead.php?no=823773</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology (ASCO®) for its exceptional scientific program. “It is the 8th consecutive year that ASCO® has endorsed this unique scientific forum, that has beco...]]></description><pubDate>Wed, 20 Apr 2016 19:00:00 +0900</pubDate></item><item><title><![CDATA[미국 임상종양학회(ASCO®), WIN 2016 심포지엄 지지: 암환자 치료 결과 향상을 위한 혁신적 접근방식]]></title><link>https://www.newswire.co.kr/newsRead.php?no=823774</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN 컨소시엄(WIN Consortium, 이하 WIN)이 “암환자 치료 결과 향상을 위한 혁신적 접근방식”에 중점을 둔 이번 심포지엄이 미국 임상종양학회(American Society of Clinical Oncology, 이하 ASCO®)에 의해 탁월한 과학 프로그램으로 지지를 받았다고 밝혔다. 앤더슨 암센터 산하 맞춤식 암치료 연구소(MD Anderson Institute for Personalized Cancer Therapy) 이사 겸 WIN...]]></description><pubDate>Wed, 20 Apr 2016 19:00:00 +0900</pubDate></item><item><title><![CDATA[WIN 2016 Symposium June 27-28, Paris: “Innovative Approaches to Improve Cancer Patient Outcomes”]]></title><link>https://www.newswire.co.kr/newsRead.php?no=812560</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration. This year WIN has chosen to address the critical question facing cancer research...]]></description><pubDate>Tue, 15 Dec 2015 20:00:00 +0900</pubDate></item><item><title><![CDATA[WIN 2016 심포지엄, 2016년 6월 27~28일 파리서 개최: “암 환자 치료 결과를 향상시키기 위한 혁신적 접근방식”]]></title><link>https://www.newswire.co.kr/newsRead.php?no=812561</link><description><![CDATA[빌쥐프, 프랑스--(Business Wire/뉴스와이어)--WIN2016 심포지엄이 프랑스 파리에서 2016년 6월 27~28일 양일간 개최될 예정이다. 이번 심포지엄은 세계적 차원의 협력을 통한 맞춤형 암 치료제의 발전을 도모하기 위해 구성된 세계 혁신 네트워크 구축 컨소시엄(Worldwide Innovative Networking[WIN] Consortium)이 주관하는 8번째 행사이다.    WIN 컨소시엄은 이번 심포지엄에서 암 연구의 중요한 당면 문제: ‘어떻게...]]></description><pubDate>Tue, 15 Dec 2015 20:00:00 +0900</pubDate></item><item><title><![CDATA[WIN Consortium Appoints Professor Waun Ki Hong as Special Advisor to Oversee Its Combined Targeted Triple-Therapy Strategy Aiming to Achieve Significant Impact on Survival in Metastatic Lung Cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=788612</link><description><![CDATA[PARIS--(Business Wire/Korea Newswire)--Worldwide Innovative Networking - WIN Consortium  announces today the appointment of Professor Waun Ki Hong from the University of Texas MD Anderson Cancer Center, as Special Advisor and member of the Executive Committee. Professor Waun Ki Hong will oversee the new strategy of WIN consortium and the next generation of clinical trials aiming to s...]]></description><pubDate>Tue, 14 Apr 2015 19:00:00 +0900</pubDate></item><item><title><![CDATA[WIN컨소시엄, 홍완기 교수 특별자문 선임…표적 트리플 치료 결합 전략 감독]]></title><link>https://www.newswire.co.kr/newsRead.php?no=788614</link><description><![CDATA[파리--(Business Wire/뉴스와이어)--세계 혁신 네트워크 구축(Worldwide Innovative Networking)-WIN컨소시엄(WIN Consortium, )이 홍완기 텍사스대MD앤더슨 암센터(University of Texas MD Anderson Cancer Center) 교수를 특별 자문위원 겸 집행위원회 위원으로 선임했다고 오늘 발표했다. 홍완기 교수는 WIN컨소시엄의 새로운 전략과 폐암 환자의 전반 생존율에 획기적인 영향을 기대하고 있는 차세대 임상 ...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2015/04/20150413102052_6454252313.jpg]]></url></image><pubDate>Tue, 14 Apr 2015 19:00:00 +0900</pubDate></item><item><title><![CDATA[WIN Consortium in Personalized Cancer Medicine Welcomes Six New Member Organizations during the WIN 2014 Symposium]]></title><link>https://www.newswire.co.kr/newsRead.php?no=757483</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine proudly announces that six new organizations were approved as WIN Consortium members during the Consortium’s 2014 WIN Symposium, held June 23-24 in Paris, France. Joining the Consortium are: Asan Medical Center (Korea), Cambridge Cancer Center (UK), Cancer Resea...]]></description><pubDate>Mon, 07 Jul 2014 18:00:00 +0900</pubDate></item><item><title><![CDATA[WIN 컨소시엄, WIN 2014 심포지엄 기간 동안 ‘맞춤형 암치료’ 분야의 새로운 멤버로 여섯 개 단체 승인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=757486</link><description><![CDATA[빌레쥐프, 프랑스--(Business Wire/뉴스와이어)--맞춤형 암치료 분야의 세계 혁신 네트워크(The Worldwide Innovative Networking, 이하 WIN) 컨소시엄이 6월 23일~24일 프랑스 파리에서 열린 2014 WIN 심포지엄(WIN Symposium) 기간 동안 여섯 개의 단체를 새로운 WIN 컨소시엄 협력체로 승인했다고 발표했다. 이번에 컨소시엄에 합류한 업체는 다음과 같다. △서울아산병원(Asan Medical Center) (한국), △캠브리지 암센터...]]></description><pubDate>Mon, 07 Jul 2014 18:00:00 +0900</pubDate></item><item><title><![CDATA[ASCO, ESMO, EORTC, ESO, and UICC Continue Endorsing the WIN Symposium Series in 2014]]></title><link>https://www.newswire.co.kr/newsRead.php?no=747043</link><description><![CDATA[VILLEJUIF, France--(Business Wire/Korea Newswire)--Five major cancer organizations which have endorsed previous events in the WIN Symposium Series, are also endorsing the WIN 2014 Symposium, to be held in Paris, June 23 - 24. The high scientific level and expected strong impact of this symposium are reflected by endorsements received from ASCO*, ESMO, EORTC, ESO, and UICC .  Exceptional agenda f...]]></description><pubDate>Thu, 17 Apr 2014 15:45:00 +0900</pubDate></item><item><title><![CDATA[ASCO, ESMO, EORTC, ESO, UICC 등 세계 주요 암 기관, 지난해 이어 ‘WIN 심포지엄’ 지지 재확인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=747044</link><description><![CDATA[빌레쥐프, 프랑스--(Business Wire/뉴스와이어)--지난해 WIN심포지엄(WIN Symposium)에 지지를 표명했던 주요 암 기관 5곳이 올해 6월 23~24일 파리에서 열릴 ‘WIN 2014 심포지엄’에 대해서도 지지를 밝혔다. 미국 임상종양학회(ASCO*), 유럽 종양내과학회(ESMO), 유럽 암 연구 및 치료기구(EORTC), 유럽 종양학회(ESO), 국제 암억제 연합(UICC, )의 지지는 심포지엄의 높은 과학 수준과 영향력을 반영하는 것이다.   최고 ...]]></description><pubDate>Thu, 17 Apr 2014 15:45:00 +0900</pubDate></item><item><title><![CDATA[WIN Consortium Appoints Winston and Strawn LLP as Official Legal Counsel]]></title><link>https://www.newswire.co.kr/newsRead.php?no=738738</link><description><![CDATA[Paris--(Business Wire/Korea Newswire)--The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine,  is proud to announce Winston and Strawn LLP  has been appointed as their official legal advisor. WIN is a global network of leading academic, industry, payors and patient advocacy organizations working to make precision cancer care a reality for patients worldwid...]]></description><pubDate>Tue, 25 Feb 2014 20:00:00 +0900</pubDate></item><item><title><![CDATA[WIN컨소시엄, 윈스턴 앤 스트론 LLP를 법률 자문회사로 선정]]></title><link>https://www.newswire.co.kr/newsRead.php?no=738740</link><description><![CDATA[파리, 프랑스--(Business Wire/뉴스와이어)--맞춤형 암 치료 분야를 대표하는 WIN컨소시엄(The Worldwide Innovative Network Consortium, )이 윈스턴 앤 스트론LLP(Winston and Strawn LLP, )를 컨소시엄의 공식 법률 자문회사로 선정했다. WIN은 전세계 환자를 위한 정확한 암 치료를 실현하는 데 앞장서고 있는 학계, 업계, 보험기관, 환자권익단체로 구성된 글로벌 네트워크이다. WIN의 목표는 향후 3년 이내에 암 ...]]></description><pubDate>Tue, 25 Feb 2014 20:00:00 +0900</pubDate></item><item><title><![CDATA[AstraZeneca, DKFZ and EORTC Join WIN Consortium]]></title><link>https://www.newswire.co.kr/newsRead.php?no=734575</link><description><![CDATA[Paris--(Business Wire/Korea Newswire)--The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine is proud to announce that AstraZeneca, DKFZ and EORTC have joined the Consortium. WIN is a unique global network of leading academics, industries, payors and patient advocacy organizations working to make cancer precision medicine a reality for patients worldwide. ...]]></description><pubDate>Mon, 27 Jan 2014 20:00:00 +0900</pubDate></item></channel></rss>